Madrigal Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Madrigal Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Madrigal Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Madrigal Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Madrigal Pharmaceuticals Inc (Madrigal) is a biopharmaceutical company that focuses on developing novel therapeutics for non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH). The company's lead product Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist. The company’s clinical pipeline includes pivotal trials for Rezdiffra: Maestro-NASH, Maestro-NAFLD-1, Maestro-NAFLD-OLE, and Maestro-NASH outcomes. Rezdiffra is designed to target key underlying causes of MASH and is indicated for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis. The company collaborates with experts in hepatology to study the therapeutic potential of THR-beta agonism. Madrigal is headquartered in West Conshohocken, Pennsylvania, the US.
Headquarters
United States of America
Address
200 Barr Harbor Drive, Suite 200, West Conshohocken, Pennsylvania, 19428
Website
www.madrigalpharma.com
Telephone
1 267 8242827
No of Employees
915
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MDGL (NASD)
Revenue (2024)
$958.4M
432.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
38.1%
(2024 vs 2023)
Market Cap*
$12.4B
Net Profit Margin (2024)
XYZ
88.4%
(2024 vs 2023)
* As of and is in US$
Madrigal Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Resmetirom: Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Rezdiffra |
| Pipeline: | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In February, the company entered into a global license agreement with Suzhou Ribo Life Science Co. Ltd. (Ribo) and its subsidiary Ribocure Pharmaceuticals AB (Ribocure) for six preclinical small interfering RNA (siRNA) programs. |
| 2025 | Contracts/Agreements | In July, the company secured a US$500 million senior secured credit facility from Blue Owl Capital to advance its MASH pipeline. |
| 2024 | Contracts/Agreements | In December, the company entered into a commercial supply agreement with Evonik Corporation, to manufacture and supply resmetirom, the API in Rezdiffra. |
Competitor Comparison
| Key Parameters | Madrigal Pharmaceuticals Inc | Eli Lilly and Co | Novo Nordisk AS | Boehringer Ingelheim International GmbH | Mirum Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Denmark | Germany | United States of America |
| City | West Conshohocken | Indianapolis | Bagsvaerd | Ingelheim am Rhein | Foster City |
| State/Province | Pennsylvania | Indiana | - | Rheinland-Pfalz | California |
| No. of Employees | 915 | 50,605 | 64,974 | 54,300 | 322 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Julian C. Baker | Chairman | Executive Board | 2023 | 59 |
| Bill Sibold | Chief Executive Officer; Director | Executive Board | 2023 | 59 |
| Mardi C. Dier | Executive Vice President; Chief Financial Officer | Senior Management | 2024 | 62 |
| Ronald Filippo | Executive Vice President; Chief Information Officer | Senior Management | 2023 | - |
| David Soergel | Chief Medical Officer; Executive Vice President | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer